ArticleMedicine2025
Comparisons of mortality predictions of mROX, CURB-65, and APACHE II in patients with severe pneumonia: A retrospective cohort study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CURB-65 for community-acquired pneumonia severity using severity index.Bioinformation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study investigates the efficacy of the modified respiratory rate oxygenation (mROX) index, the CURB-65 score, their combination, and the Acute Physiology and Chronic Health Evaluation (APACHE) II score in predicting mortality among patients with severe pneumonia over various time frames. This retrospective cohort study analyzed data from patients admitted with severe pneumonia between January 2017 and December 2023. Patient demographics and 7-, 14-, and 28-day mortality outcomes were collected. The mROX, CURB-65, and APACHE II scores were computed upon hospital admission. The receiver operating characteristic (ROC) curve, time-dependent ROC curve, and survival curve analyses were conducted to assess the mortality predictive performance of mROX, CURB-65, and their combination, as well as APACHE II. The study included 140 patients, of whom 100 (71.4%) were male, with a median age of 65.0 years (interquartile range: 24.0). Within 28 days, 91 (65.0%) patients had succumbed. Compared to survivors, deceased patients exhibited higher CURB-65 scores and lower mROX indices. ROC analysis indicated that mROX outperformed CURB-65 and APACHE II in sensitivity, accuracy, and area under the curve (AUC) for predicting 28-day mortality. The combination of mROX and CURB-65 yielded the highest AUC (72.1%), suggesting enhanced mortality prediction accuracy. Time-dependent ROC and AUC analyses demonstrated the superior predictive capability of APACHE II within the initial 7 days post-admission, while mROX and CURB-65, alone or combined, were more effective for predictions beyond 14 days. Kaplan-Meier survival analysis indicated that higher mROX values and lower scores of CURB-65 and the combination of both were associated with reduced mortality risk, whereas APACHE II showed no significant difference in mortality risk. The mROX index, particularly when combined with CURB-65, improves mortality prediction accuracy in severe pneumonia patients beyond 14 days post-admission. The APACHE II score remains a valuable predictor within the first 7 days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.